{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:43:43Z","timestamp":1769579023569,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41397-018-0041-5","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T16:17:16Z","timestamp":1535991436000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis"],"prefix":"10.1038","volume":"19","author":[{"given":"Eric","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuwan C.","family":"Hettige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwyneth","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement C.","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nela","family":"Pivac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matea","family":"Nikolac Perkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"41_CR1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2165\/11595380-000000000-00000","volume":"25","author":"MJ Arranz","year":"2011","unstructured":"Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25:933\u201369.","journal-title":"CNS Drugs"},{"key":"41_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1517\/17425255.2015.1075003","volume":"11","author":"V Sriretnakumar","year":"2015","unstructured":"Sriretnakumar V, Huang E, M\u00fcller DJ. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert Opin Drug Metab Toxicol. 2015;11:1709\u201331.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"41_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"MJ Arranz","year":"2007","unstructured":"Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12:707\u201347.","journal-title":"Mol Psychiatry"},{"key":"41_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(96)91594-9","volume":"347","author":"D Vojvoda","year":"1996","unstructured":"Vojvoda D, Grimmell K, Sernyak M. Monozygotic twins concordant for response to clozapine. Lancet. 1996;347:61.","journal-title":"Lancet"},{"key":"41_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1192\/bjp.178.1.86","volume":"178","author":"I Mata","year":"2001","unstructured":"Mata I, Madoz V, Arranz MJ, Sham P, Murray RM. Olanzapine: concordant response in monozygotic twins with schizophrenia. Br J Psychiatry. 2001;178:86.","journal-title":"Br J Psychiatry"},{"key":"41_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1600-0447.2001.00401.x","volume":"104","author":"DJ M\u00fcller","year":"2001","unstructured":"M\u00fcller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand. 2001;104:375\u201399.","journal-title":"Acta Psychiatr Scand"},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.psychres.2004.02.018","volume":"133","author":"PM Wehmeier","year":"2005","unstructured":"Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res. 2005;133:273\u20136.","journal-title":"Psychiatry Res"},{"key":"41_CR8","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1073\/pnas.87.20.8060","volume":"87","author":"KR Jones","year":"1990","unstructured":"Jones KR, Reichardt LF. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA. 1990;87:8060\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"41_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1460-9568.1995.tb01058.x","volume":"7","author":"L Studer","year":"1995","unstructured":"Studer L, Spenger C, Seiler RW, Altar CA, Lindsay RM, Hyman C. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra. Eur J Neurosci. 1995;7:223\u201333.","journal-title":"Eur J Neurosci"},{"key":"41_CR10","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1523\/JNEUROSCI.4601-04.2005","volume":"25","author":"ZC Baquet","year":"2005","unstructured":"Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci. 2005;25:6251\u20139.","journal-title":"J Neurosci"},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2015.27","volume":"20","author":"M Notaras","year":"2015","unstructured":"Notaras M, Hill R, van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry. 2015;20:916\u201330.","journal-title":"Mol Psychiatry"},{"key":"41_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00213-012-2643-y","volume":"222","author":"XY Zhang","year":"2012","unstructured":"Zhang XY, Liang J, Xiu MH, De Yang F, Kosten TA, Kosten TR. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacol. 2012;222:277\u201384.","journal-title":"Psychopharmacol"},{"key":"41_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jpsychires.2006.08.007","volume":"41","author":"XY Zhang","year":"2007","unstructured":"Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res. 2007;41:997\u20131004.","journal-title":"J Psychiatr Res"},{"key":"41_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15622970802182733","volume":"10","author":"EN Rizos","year":"2008","unstructured":"Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2008;10:1\u20135.","journal-title":"World J Biol Psychiatry"},{"key":"41_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.pnpbp.2010.05.013","volume":"34","author":"JG Lee","year":"2010","unstructured":"Lee JG, Cho HY, Park SW, Seo MK, Kim YH. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1001\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"41_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000205518","volume":"59","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kim YK. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology. 2009;59:51\u201358.","journal-title":"Neuropsychobiology"},{"key":"41_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpsychires.2006.01.005","volume":"41","author":"RW Grillo","year":"2007","unstructured":"Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2007;41:31\u20135.","journal-title":"J Psychiatr Res"},{"key":"41_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","volume":"80","author":"A Luoni","year":"2014","unstructured":"Luoni A, Fumagalli F, Racagni G, Riva MA. Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacol Res. 2014;80:1\u20138.","journal-title":"Pharmacol Res"},{"key":"41_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.schres.2013.09.027","volume":"151","author":"CD Pandya","year":"2013","unstructured":"Pandya CD, Hoda MN, Kutiyanawalla A, Buckley PF, Pillai A. Differential effects upon brain and serum BDNF levels in rats as response to continuous and intermittent administration strategies of two second generation antipsychotics. Schizophr Res. 2013;151:287\u20138.","journal-title":"Schizophr Res"},{"key":"41_CR20","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1523\/JNEUROSCI.0348-04.2004","volume":"24","author":"ZY Chen","year":"2004","unstructured":"Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF)(Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004;24:4401\u201311.","journal-title":"J Neurosci"},{"key":"41_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","volume":"112","author":"MF Egan","year":"2003","unstructured":"Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257\u201369.","journal-title":"Cell"},{"key":"41_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0304-3940(03)00828-0","volume":"349","author":"CJ Hong","year":"2003","unstructured":"Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett. 2003;349:206\u20138.","journal-title":"Neurosci Lett"},{"key":"41_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pnpbp.2012.05.014","volume":"39","author":"GC Zai","year":"2012","unstructured":"Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:96\u2013101.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"41_CR24","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1007\/s00213-014-3515-4","volume":"231","author":"M Nikolac Perkovic","year":"2014","unstructured":"Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacol. 2014;231:3757\u201364.","journal-title":"Psychopharmacol"},{"key":"41_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00702-004-0233-9","volume":"112","author":"S Anttila","year":"2005","unstructured":"Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm. 2005;112:885\u201390.","journal-title":"J Neural Transm"},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ejhg.2009.238","volume":"18","author":"M Xu","year":"2010","unstructured":"Xu M, Li S, Xing Q, Gao R, Feng G, Lin Z, et al. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur J Hum Genet. 2010;18:707\u201312.","journal-title":"Eur J Hum Genet"},{"key":"41_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000327605","volume":"65","author":"CU Pae","year":"2012","unstructured":"Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology. 2012;65:1\u201311.","journal-title":"Neuropsychobiology"},{"key":"41_CR28","first-page":"357","volume":"16","author":"Q Xu","year":"2016","unstructured":"Xu Q, Wu X, Li M, Huang H, Minica C, Yi Z, et al. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. Pharm J. 2016;16:357\u201365.","journal-title":"Pharm J"},{"key":"41_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"41_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.mp.4001926","volume":"12","author":"A Serretti","year":"2007","unstructured":"Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247\u201357.","journal-title":"Mol Psychiatry"},{"key":"41_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","volume":"167","author":"JP Zhang","year":"2010","unstructured":"Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167:763\u201372.","journal-title":"Am J Psychiatry"},{"key":"41_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FPC.0000000000000132","volume":"25","author":"M Mitjans","year":"2015","unstructured":"Mitjans M, Catal\u00e1n R, V\u00e1zquez M, Gonz\u00e1lez-Rodr\u00edguez A, Penad\u00e9s R, Pons A, et al. Hypothalamic\u2013pituitary\u2013adrenal system, neurotrophic factors and clozapine response: association with FKBP5 and NTRK2 genes. Pharm Genom. 2015;25:274\u20137.","journal-title":"Pharm Genom"},{"key":"41_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12031-014-0482-5","volume":"56","author":"T Terzi\u0107","year":"2015","unstructured":"Terzi\u0107 T, Kastelic M, Dol\u017ean V, Plesni\u010dar BK. Genetic variability testing of neurodevelopmental genes in schizophrenic patients. J Mol Neurosci. 2015;56:205\u201311.","journal-title":"J Mol Neurosci"},{"key":"41_CR34","doi-asserted-by":"publisher","first-page":"e102556","DOI":"10.1371\/journal.pone.0102556","volume":"9","author":"H Kaur","year":"2014","unstructured":"Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S, et al. Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients. PLoS ONE. 2014;9:e102556.","journal-title":"PLoS ONE"},{"key":"41_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hup.1257","volume":"27","author":"R Yoshimura","year":"2012","unstructured":"Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, et al. Aripiprazole altered plasma levels of brain\u2010derived neurotrophic factor and catecholamine metabolites in first\u2010episode untreated Japanese schizophrenia patients. Human Psychopharmacol Clin Exp. 2012;27:33\u20138.","journal-title":"Human Psychopharmacol Clin Exp"},{"key":"41_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eurpsy.2015.12.001","volume":"33","author":"S. Cargnin","year":"2016","unstructured":"Cargnin\u00a0S, Massarotti\u00a0A,\u00a0Terrazzino S. BDNF Val66Met\u00a0and clinical response to antipsychotic drugs: a systematic review and meta-analysis. Eur Psychiatry. 2016;33:45\u201353.","journal-title":"European Psychiatry"},{"issue":"6","key":"41_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/FPC.0b013e3282f85e26","volume":"18","author":"Ming-Qing Xu","year":"2008","unstructured":"Xu MQ, St Clair D, Feng GY, Lin ZG, He G, Li XW, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharm Genom. 2008;18:449\u201357.","journal-title":"Pharmacogenetics and Genomics"},{"issue":"9","key":"41_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/mp.2014.117","volume":"20","author":"B S Fernandes","year":"2014","unstructured":"Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics:\u00a0meta-analysis\u00a0and implications. Mol Psychiatry. 2015;20:1108\u201319.","journal-title":"Molecular Psychiatry"},{"issue":"4","key":"41_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/mp.2012.38","volume":"18","author":"J P Lopez","year":"2012","unstructured":"Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT,\u00a0et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2013;18:398.","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"41_CR40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00213-010-1956-y","volume":"212","author":"Xiang Yang Zhang","year":"2010","unstructured":"Zhang XY, Xiu MH, De Yang F, Wu GY, Lu L, Kosten TA, et al. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacol. 2010;212:301\u20137.","journal-title":"Psychopharmacology"},{"issue":"9","key":"41_CR41","doi-asserted-by":"publisher","first-page":"e74264","DOI":"10.1371\/journal.pone.0074264","volume":"8","author":"Zheng Lin","year":"2013","unstructured":"Lin Z, Su Y, Zhang C, Xing M, Ding W, Liao L, et al. The interaction of BDNF and NTRK2 gene increases the susceptibility of paranoid schizophrenia. PLoS ONE. 2013;8:e74264.","journal-title":"PLoS ONE"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0041-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:59:37Z","timestamp":1684616377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-018-0041-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1038\/s41397-018-0041-5","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JLK has acted as a consultant or received honoraria from GlaxoSmith-Kline, Sanofi-Aventis, Dainippon-Sumitomo, Novartis, Shire, Eli Lilly, and Roche; he is on a Scientific Advisory Board member (unpaid) of AssureRx Health Inc. The remaining authors have no potential conflicts of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}